| Literature DB >> 9484503 |
D Kikelj1, S Pecar, V Kotnik, A Stalc, B Wraber-Herzog, S Simcic, A Ihan, L Klamfer, L Povsic, R Grahek, E Suhadolc, M Hocevar, H Hönig, R Rogi-Kohlenprath.
Abstract
A novel non-pyrogenic carbocyclic muramyl dipeptide (MDP) analogue, N-¿trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl¿-L-alanyl-D-glutamic acid, was obtained by replacement of the N-acetylmuramic acid part and the D-isoglutamine residue of the MDP molecule by a trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl moiety and D-glutamic acid, respectively. The title compound was selected as a promising candidate for further evaluation among several related analogues on the basis of an immunorestoration test in mice. This novel nor-MDP analogue protects mice against the immunosuppressive effect of cyclophosphamide and increases the nonspecific resistance of mice against fungal infection. It is an immunomodulator which enhances the maturation of lymphocytes B to plasma cells and increases the activity of lymphocytes B and lymphocytes T as well as that of macrophages but does not alter the number of these cells.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9484503 DOI: 10.1021/jm970509d
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446